This article addresses how pharmaceutical companies take precautions against activist firms when using their shares as currency for an acquisition. These bans have gone largely unnoticed by the activist managers, who say shareholders may be harmed when a company limits who can buy its shares.
Members-only access
To access the full resource, you must be a
member.
Already a member?
Login to unlock.
Login
Not an ACC member?
Gain access to a comprehensive collection of global
resources for in-house counsel
Sign
up for a 30-day trial
Region:
United States
The information in any resource collected in this virtual library should
not be construed as legal advice or legal opinion on specific facts and should not be considered representative of the views of its authors, its sponsors, and/or ACC. These resources are not intended as a definitive statement on the subject addressed. Rather, they are intended to serve as a tool providing practical advice and references for the busy in-house practitioner and other readers.